title: Money for drugs: should physicians be paid for pharmaceutical development and clinical investigations?
authors.affiliation: University of Missouri-Kansas City, USA. vanwayc@umkc.edu
authors.forename: Charles
authors.initials: C
authors.lastname: Van Way
authors.forename: George
authors.initials: G
authors.lastname: Bohigian
authors.forename: Art
authors.initials: A
authors.lastname: Gale
authors.forename: Marjorie
authors.initials: M
authors.lastname: Powell
authors.forename: John C
authors.initials: JC
authors.lastname: Hagan
mesh_terms: D016265:Conflict of Interest; D004345:Drug Industry / Q000191:economics / Q000941:ethics*; D032984:Ethics, Research; D006801:Humans; D007182:Income; D033181:Information Dissemination; D007400:Interprofessional Relations / Q000941:ethics*; D010820:Physicians / Q000191:economics / Q000941:ethics*; D012109:Research Support as Topic / Q000941:ethics
references.citation: JAMA. 2003 Jan 22-29;289(4):454-65
references.pmid: 12533125
references.citation: JAMA. 2011 Mar 9;305(10):1008-17
references.pmid: 21386079